Literature DB >> 30249686

Site-Directed Mutagenesis of the 1,3-β-Glucan Synthase Catalytic Subunit of Pneumocystis jirovecii and Susceptibility Assays Suggest Its Sensitivity to Caspofungin.

A Luraschi1, S Richard1, P M Hauser2.   

Abstract

The echinocandin caspofungin inhibits the catalytic subunit Gsc1 of the enzymatic complex synthesizing 1,3-β-glucan, an essential compound of the fungal wall. Studies with rodents showed that caspofungin is effective against Pneumocystis asci. However, its efficacy against asci of Pneumocystis jirovecii, the species infecting exclusively humans, remains controversial. The aim of this study was to assess the sensitivity to caspofungin of the P. jirovecii Gsc1 subunit, as well as of those of Pneumocystis carinii and Pneumocystis murina infecting, respectively, rats and mice. In the absence of an established in vitro culture method for Pneumocystis species, we used functional complementation of the Saccharomyces cerevisiae gsc1 deletant. In the fungal pathogen Candida albicans, mutations leading to amino acid substitutions in Gsc1 confer resistance to caspofungin. We introduced the corresponding mutations into the Pneumocystis gsc1 genes using site-directed mutagenesis. In spot dilution tests, the sensitivity to caspofungin of the complemented strains decreased with the number of mutations introduced, suggesting that the wild-type enzymes are sensitive. The MICs of caspofungin determined by Etest and YeastOne for strains complemented with Pneumocystis enzymes (respectively, 0.125 and 0.12 μg/ml) were identical to those upon complementation with the enzyme of C. albicans, for which caspofungin presents low MICs. However, they were lower than the MICs upon complementation with the enzyme of the resistant species Candida parapsilosis (0.19 and 0.25 μg/ml). Sensitivity levels of Gsc1 enzymes of the three Pneumocystis species were similar. Our results suggest that P. jirovecii is sensitive to caspofungin during infections, as are P. carinii and P. murina.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Pneumocystiszzm321990; drug resistance; drug sensitivity; echinocandins; heterologous functional complementation

Mesh:

Substances:

Year:  2018        PMID: 30249686      PMCID: PMC6256769          DOI: 10.1128/AAC.01159-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

1.  T-Coffee: A novel method for fast and accurate multiple sequence alignment.

Authors:  C Notredame; D G Higgins; J Heringa
Journal:  J Mol Biol       Date:  2000-09-08       Impact factor: 5.469

Review 2.  Pneumocystis pneumonia.

Authors:  Charles F Thomas; Andrew H Limper
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

3.  Dihydropteroate synthase polymorphisms in Pneumocystis carinii.

Authors:  B R Lane; J C Ast; P A Hossler; D P Mindell; M S Bartlett; J W Smith; S R Meshnick
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

4.  Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis.

Authors:  T Mio; M Adachi-Shimizu; Y Tachibana; H Tabuchi; S B Inoue; T Yabe; T Yamada-Okabe; M Arisawa; T Watanabe; H Yamada-Okabe
Journal:  J Bacteriol       Date:  1997-07       Impact factor: 3.490

5.  A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.

Authors:  Eleusa Maria F Rocha; Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

6.  Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia.

Authors:  K Beltz; C M Kramm; H-J Laws; H Schroten; R Wessalowski; U Göbel
Journal:  Klin Padiatr       Date:  2006 May-Jun       Impact factor: 1.349

7.  Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

Authors:  M B Kurtz; G Abruzzo; A Flattery; K Bartizal; J A Marrinan; W Li; J Milligan; K Nollstadt; C M Douglas
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

Review 8.  Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.

Authors:  Guo-Wei Tu; Min-Jie Ju; Ming Xu; Rui-Ming Rong; Yi-Zhou He; Zhang-Gang Xue; Tong-Yu Zhu; Zhe Luo
Journal:  Nephrology (Carlton)       Date:  2013-11       Impact factor: 2.506

9.  A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase.

Authors:  C M Douglas; J A Marrinan; W Li; M B Kurtz
Journal:  J Bacteriol       Date:  1994-09       Impact factor: 3.490

10.  Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase.

Authors:  P Mazur; N Morin; W Baginsky; M el-Sherbeini; J A Clemas; J B Nielsen; F Foor
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

View more
  2 in total

1.  Highly Conserved gsc1 Gene of Pneumocystis jirovecii in Patients with or without Prior Exposure to Echinocandins.

Authors:  Pierre L Bonnet; Solène Le Gal; Claire V Hoffmann; Florent Morio; Fouleymata Diabira; Athéna de Quélen; Guillaume Curral; Steven Negri; Virginie Cogulet; Jean-François Huon; Matthieu Grégoire; Nicolas Papon; Patrice Le Pape; Jean-Philippe Bouchara; Gilles Nevez
Journal:  Antimicrob Agents Chemother       Date:  2021-11-01       Impact factor: 5.938

Review 2.  On the Treatment of Pneumocystis jirovecii Pneumonia: Current Practice Based on Outdated Evidence.

Authors:  Emily G McDonald; Guillaume Butler-Laporte; Olivier Del Corpo; Jimmy M Hsu; Alexander Lawandi; Julien Senecal; Zahra N Sohani; Matthew P Cheng; Todd C Lee
Journal:  Open Forum Infect Dis       Date:  2021-10-29       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.